November 1, 2018: The Johnson and Johnson (J&J) company vision is for a World Without Disease and their strategy to reach this goal is summed up by;
1) earlier/better prevention, 2) early disease interception and 3) cures.
To fuel this vision J&J builds partnerships with innovative companies developing high quality technology that supports an unmet health-related need and fits with J&J’s strategic focus. But J&J doesn’t stop there, they also accept scientifically promising startups into JLABS; their innovation and incubation program that has nine facilities in the USA, one in Toronto, Canada and another opening soon in Shanghai, China. Entos Pharmaceuticals is one of four promising Therapeutics-focused startups offered residency into J&J’s flagship innovation facility, JLABS San Diego, that supports 60 startups in total. The program offers lab facilities, mentorship and networking events aimed at helping these emerging companies to succeed.
“We also incubate startups … they can develop their product without large expenses and focus on what they are best at: their science and making their idea ready for the consumer. If then it looks interesting and falls into our strategic focus, we may sit down and discuss whether they’d like to tighten that partnership – but they’re completely independent and don’t have to promise us anything,” Oliver Stohlmann, J&J’s global head of external innovation communication.
Read more: https://pharmaphorum.com/views-and-analysis/johnson-johnson-partnering-to-eliminate-disease/
JLABS San Diego: https://jlabs.jnjinnovation.com/companies?f%5B0%5D=company_location%3A1836&f%5B1%5D=company_prop%3Acurrent